Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

BBridgeBio Pharma, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
B

BridgeBio Pharma, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
    Sep 23, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Sep 18, 2026BridgeBio Pharma Inc. Press Releases
  • Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
    Sep 9, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
    Sep 2, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio to Participate in September Investor Conferences
    Sep 1, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
    Aug 31, 2026BridgeBio Pharma Inc. Press Releases
  • Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
    Aug 30, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
    Aug 26, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
    Aug 24, 2026BridgeBio Pharma Inc. Press Releases
  • BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
    Aug 14, 2026BridgeBio Pharma Inc. Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$66.50Close ยท Oct 7, 2026